The latest recommendations on the use of new oral anticoagulants in routine practice

• Main Authors: Michał Witkowski, Magdalena Witkowska, Piotr Smolewski
• Format: Article
• Language: English
• Published: Index Copernicus International S.A. 2016-02-01
• Series: Postępy Higieny i Medycyny Doświadczalnej
• Subjects: nowe leki przeciwkrzepliwe; migotanie przedsionków; anticoagulant treatment; dabigatran; rywaroksaban; apiksaban
• Online Access: http://phmd.pl/gicid/01.3001.0009.6782

The use of non-vitamin K antagonist oral anticoagulants (NOACs) has become a breakthrough in anticoagulant treatment and it is expected to rise significantly in upcoming years. The use of conventional anticoagulants have several limitations: subcutaneous administration of heparin, or close monitoring of INR during application of vitamin K antagonists. In the last decade, target-specific oral anticoagulants (TSOAC) including dabigatran, rivaroxaban, apixaban, edoxaban have been marketed for prophylaxis and treatment. Therefore, it is crucial to understand the potential uses, side effects, and management of these agents in routine practice. NOACs have major pharmacologic advantages, including a rapid onset and offset of action, fewer drug interactions than conventional anticoagulants, and predictable pharmacokinetics. These agents are gaining popularity among both physicians and patients because of their easiness of administration and the eliminating the requirement for regular coagulation monitoring. In this review, we focus on discussing practical recommendations for the use of NOACs and the risks and benefits of incorporating them into routine practice.